<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20190801062500Z</creation_date><modification_date>D:20210723094100Z</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-16-1158_h_dec_3.pdf</pdf_file></head><body><section><header>enen</header><p>european commission
 brussels, 20.8.2021c(2021)6283 (final)</p></section><section><header>commission implementing decisionof 20.8.2021
 on the renewal of the marketing authorisation for the medicinal product for human use 
 &quot;afstyla - lonoctocog alfa&quot;, granted by decision c(2017)44(final)</header><p>(text with eea relevance) (only the german text is authentic)</p></section><section><header>en</header><p>1</p></section><section><header>en</header></section><section><header>commission implementing decisionof 20.8.2021
 on the renewal of the marketing authorisation for the medicinal product for human use 
 &quot;afstyla - lonoctocog alfa&quot;, granted by decision c(2017)44(final)</header><p>(text with eea relevance)(only the german text is authentic)
 the european commission,
 having regard to the treaty on the functioning of the european union,
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a european 
 medicines agency
 1, and in particular article 10(2) thereof,having regard to the application submitted by csl behring gmbh, on 9 march 2021, under 
 article 14(2) of regulation (ec) no 726/2004 with a view to the renewal of the marketing 
 authorisation for the medicinal product &quot;afstyla - lonoctocog alfa&quot;,
 having regard to the opinion of the european medicines agency, formulated on 24 june 
 2021 by the committee for medicinal products for human use,
 whereas:
 (1)
 on the basis of a re-evaluation by the agency of the risk-benefit balance following 
 the consideration of a consolidated file, it appears that the medicinal product 
 &quot;afstyla - lonoctocog alfa&quot;, entered in the union register of medicinal products 
 under 
 number 
 eu/1/16/1158 
 and 
 authorised 
 by 
 commission 
 decision 
 c(2017)44(final) of 4 january 2017, complies with the requirements set out in 
 directive 2001/83/ec of the european parliament and of the council of 6 november 
 2001 on the community code relating to medicinal products for human use
 2.(2)
 the marketing authorisation which expires on 6 january 2022 should therefore be 
 renewed.
 (3)
 decision c(2017)44(final) should therefore be amended accordingly. the union 
 register of medicinal products should also be updated.
 (4)
 for the sake of clarity and transparency, it is appropriate, following the amendment of 
 part or parts of the annexes, to provide for a consolidated version thereof. the 
 annexes to decision c(2017)44(final) should therefore be replaced.
 (5)
 the measures provided for in this decision are in accordance with the opinion of the 
 standing committee on medicinal products for human use,
 1oj l 136, 30.4.2004, p. 1.2oj l 311, 28.11.2001, p. 67.</p></section><section><header>en</header><p>2</p></section><section><header>en</header><p>has adopted this decision:article 1the marketing authorisation granted by decision c(2017)44(final) of 4 january 2017 which expires on 6 january 2022 is renewed.
 article 2decision c(2017)44(final) is amended as follows:1) annex i is replaced by the text set out in annex i to this decision;
 2) annex ii is replaced by the text set out in annex ii to this decision;
 3) annex iii is replaced by the text set out in annex iii to this decision.
 article 3this decision is addressed to csl behring gmbh, emil-von-behring-stra√üe 76, 35041 marburg, deutschland.
 done at brussels, 20.8.2021
 for the commissionsandra gallina
 director-general</p></section></body></xml>